APRIL 30TH-MAY 2ND
MILAN - ITALY
ISNS 2016 BIANNUAL MEETING

APRIL 30TH    |     Istituto Europeo di Oncologia - via ripamonti, 435 Milan
MAY 1ST - 2ND    |     Nhow Hotel - via tortona, 35 Milan

CHAIRMEN

Nicola Mozzillo MD
Director Department Melanoma and Soft Tissue
Scientific Vice Director
Istituto Nazionale dei Tumori di Napoli
email: nimozzi@tin.it

Alessandro Testori MD
Chairman EORTC Melanoma Group 2012-2014
Chairman chirurgia/surgical subgroup
EORTC Melanoma Group
Director
Dermato-oncological division
Istituto Europeo di Oncologia
alessandro.testori@ieo.it

Dea International Events: Piazza Cavallotti 2, 00040 Castel Gandolfo (RM)
Tel. 06 9360565 - Mobile 339 6366072
companyconsulting.deaeventi@gmail.com
The sentinel Node in the era of individualized management of cancer patients

The International Sentinel Node Society serves and coordinates the needs of the diverse community of physicians and scientists who study the sentinel node. It is now clear that the sentinel node concept, as originally described in patients with melanoma, is applicable to any type of malignant tumor that has the potential to spread via lymphatics to lymph nodes. Thus sentinel node technology has now entered a new phase of discovery and treatment. This technique has great potential for individualized management of solid tumors and it is also apparent that successful application of sentinel node technology requires close cooperation between dermatologist, surgeons, pathologists, radiologists and nuclear medicine physicians.

The new era of the SNB concept should be to perform this procedure both to evaluate the real necessity to perform a radical nodal dissection as it has been demonstrated for many patients with breast cancer and to drive clinicians to prescribe new adjuvant therapies with molecular based targeting or immunologically based approaches.

These medical therapies topic is becoming more and more important in the advanced disease setting, which makes the adjuvant setting the new topic to be explored and proposed for clinical research proposals.

Similarly apart the consolidates approach in melanoma and breast cancer, a clear identification on the role of SNB in most solid tumors needs to obtain a definitive validation: guide lines discussion will be conducted on all these diseases where such procedure has not reached a well defined profile and indication.
April 30
Istituto Europeo di Oncologia, Via Ripamonti, 435 Milano - Room Direzione Scientifica

13:00 Board meeting of the steering committee

Plenary Session

14:00 Registration
15:30 Opening Ceremony
16.00 Welcome message
16:30 A tribute to Donald Morton
16:40 A tribute to Natale Cascinelli
16:50 A life dedicated to conservative surgery
17:00 AJCC melanoma staging system: towards a 8th edition
17:10 Break

SNB: future prospective

Chairmen C.M. Balch
P. Delrio

17:20 Melanoma
17:30 Breast
17:40 Head & Neck
17:50 Gastro intestinal
18:00 Colorectal
18:10 Urology
18:20 Gynecology
18:30 The role of sentinel node in the future of cancer managament
18:45 Assembly Report
19:20 Cocktail dinner (transfer by bus to Testori’s family country house)
May 1
Room MIAMI - PANAMA - DUBAI
Nhow Hotel, Via Tortona 35, Milano

Plenary Session
Sentinel Node and Technologies

Chairmen
S. Lastoria
S. Vidal Sicar

08:30 Overview of Lymphoscintigraphy
R. Uren

08:45 Enhanced receptor-targeting with Tilmanocept for lymphatic mapping
A. Wallace

09:00 Hybrid tracers for combined radioactivity/fluorescence detection
F. van Leeuwen

09:15 Indocyanine Green for Flourescence Imaging
K. Joachim

09:30 SPECT/CT for preoperative sentinel lymph node localization in areas of complex anatomy
R. Valdés Olmos

09:45 Sestamibi-guided biopsy of radiologically occult breast lesions using dedicated gamma camera devices
L. Pereira Arias

10:00 Sentinel node biopsy in early stage breast cancer with a single incision and no lymphoscintigraphy
M. Rizzo

10:15 Fluorescent identification of sentinel node in the invisible light range
R. Andtbacka

10:30 Discussion

10:45 Break
May 1
Room MIAMI - PANAMA

Plenary Session
Sentinel Node Biopsy pathologists session towards a consensus on SN sectioning

Chairmen  A. Cochran
G. Viale

11:00  The EORTC sectioning protocol  S. Koljenovic
11:15  The UCLA sectioning protocol  A. Cochran
11:30  The Australian Sectioning Protocol  L. Jackett
11:45  ITC Identification and biological significance in breast  A. Sapino

12:00  Augsburg/Rotterdam classification of Melanoma SLN metastases and its prognostic value  H. Starz
12:15  Are SN data bases comparable?  A. Van Akkooi
12:30  Intraoperative frozen sectioning in breast and melanoma  PRO & CON - A. Spatz
12:45  SLN status and computational image analyses  R. Riber-Hansen
13:00  Discussion
13:15  Lecture: Follow up randomized study on melanoma: update  A. Testori
13:30  Lunch

13.45 - 14.45  Satellite symposium by Ithera medical
May 1
Room MIAMI - PANAMA
Microstaging and clinical decisions

Chairmen
R. Andtbacka
D. Massi

14:45  Histophatolgy of positive SNB and long term outcomes  A. Cochran
15:00  Clinical role of ITC in SLN  C. R. Rossi
15:15  Cancer metastasis from tumor microenvironment to the sentinel lymph node  S. Leong
15:30  Correlation between sentinel node status and mutational profile in melanoma  G. Botti
15:45  Confocal microscopy may help to select thin melanoma patients for SNB?  G. Pellacani
16:00  Is completion LND indicated?  PRO - M. Ross
       CON - D. Coit
16:30  Discussion
16:45  Break
May 1  
**Room MIAMI - PANAMA**  
Sentinel Node Biopsy melanoma session  

**Chairmen**  
N. Mozzillo  
A. Testori  

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00</td>
<td>The role of sentinel node staging in the design and end results reporting of cancer clinical trial</td>
<td>J. Thompson</td>
</tr>
<tr>
<td>17:15</td>
<td>SLN for atypical melanocytic neoplasms</td>
<td>M. Yamamoto</td>
</tr>
<tr>
<td>17:30</td>
<td>Is there a good timing for SLN biopsy?</td>
<td>A. Tejera-Vaquerizo</td>
</tr>
<tr>
<td>17:45</td>
<td>Management of patients with positive nodes on an ectopic location of the sentinel node (epitrochlear, popliteal, trunk)</td>
<td>C. Caracò</td>
</tr>
<tr>
<td>18.00</td>
<td>Role of guided FNA in diagnosis and prognosis</td>
<td>O. Catalano</td>
</tr>
<tr>
<td>18:15</td>
<td>From open to minimally invasive lymphadenectomy: learning curve and results in quality of life</td>
<td>J. Soteldo</td>
</tr>
<tr>
<td>18:30</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>18:45</td>
<td>Closure</td>
<td></td>
</tr>
</tbody>
</table>
May 1
Room DUBAI
11:00 - 13:00 Abstract presentations and new studies proposed

11:00 - 12:00 Technologies

Chairmen P.M. Herranz, C. Grana

1. Real time integration of freehand SPECT and ultrasound for preoperative localization of sentinel lymph nodes
C Bluemel, G Safak, AK Buck, K Herrmann

2. Lymphovascular anastomosis (lympha technique)
F Boccardo, G Villa, F Casabona, CC Campisi , S Dessalvi, L Molinari, S Spinaci, C Cornacchia, M Valenzano, S Costantini, D Friedman, F Murelli, F De Cian , C Campisi

3. Sentinel node mapping using unique multimodality probes
H Fujii, K Ohnuki, K Araki, Y Tanaka, S Hamamichi, A Fujit, Io Umeda, S kosuda, A Shiotani

4. First in human use of the prototype opto nuclear probe, a hybrid modality that allows for sequential radio and near infrared fluorescence tracing during surgery
NS van den Berg, H Simon, GH KleinJan, T Engelen, A Bunschoten, MN Welling, BM Tijink, S Horenblas, J Chambron, FWB van Leeuwen

5. Factors Influencing the Sentinel Lymph Node Count: who is your pathologist?
JT Unkart, AM Wallace

6. Ph Transistor Nanoprobes for Fluorescence Detection of Occult Nodal Metastases
B Sumer, J Thibodeaux, Z Lin, T Zhao, G Huang, GC. Balch, J Gao, CM Balch

7. Development of a practical 10 min intraoperative IHC product line
Y Zhang, Z Zhang, J Wang, S Zhao, F Lin

8. The non-invasive treatment for sentinel lymph node metastasis by photodynamic therapy using verteporfin nanoparticles.
H Jinno, S Matsuda, K Shimada, T Konno, K Ishihara, Y Kitagawa
May 1
Room DUBAI
12:00 - 13:00  Technologies

Chairmen  S. Lastoria, R. Uren

1. To facilitate hybrid surgical guidance, does hardware integration of gamma and fluorescence imaging modalities make sense in the operating room?
   GH KleinJan, D Hellingman, NS van den Berg, MN van Oosterom, J Catret, S Horenblas, RA Valdes Olmos, FWB van Leeuwen

2. Near infrared fluorescence guided surgery: determination of the lower detection limit at which intraoperative fluorescence guidance is still feasible
   GH KleinJan, A Bunschoten, NS van den Berg, RA Valdes Olmos, VMC Klop, S Horenblas, HG van der Poel, HJ Wester, FWB van Leeuwen

3. Multispectral fluorescence imaging to generate a patient specific road map as a means to improve fluorescence guided surgery
   NS van den Berg, T Buckle, GH KleinJan, HG van der Poel, FWB van Leeuwen

4. A synthetic macromolecule for sentinel node detection: 99mTc DPTA Mannosyl Dextrane
   DR Vera, AM Wallace, CK Hoh, RF Mattrey

5. Lymphoseek: a molecular radiopharmaceutical for sentinel node dissection
   AM Wallace, CK Hoh, DR Vera, DD Darrah, G Schulteis

6. Fluorescent tilmanocept for tumor margin analysis in the mouse model
   A Hosseini, JL Baker, CA Tokin, Z Qin, DJ Hall, DG StupaK, T Hayashi, AM Wallace, DR Vera

7. Optimization via specific fluorescence brightness of a receptor targeted probe for optical imaging and positron emission tomography of sentinel lymph nodes
   Z Qin, DJ Hall, MA Liss, CK Hoh, CJ Kane, AM Wallace, DR Vera

8. Comparative analysis of 1% lymphazurin versus 1% methylene blue for sentinel lymph node mapping in early stage breast cancer
   S Saha, V Patel, S Grisby, D Mazzaferrro, L Berbiglia, G Paez, J Gernand, L Lawrence, D Wiese
May 1
Room DUBAI

Sentinel Node in lung cancer

Chairmen
G. Rocco
L. Santambrogio

14:45 Update on indications and study results
Y. Colson

15:00 Technical devices and new methods to detect SN
G. Rocco

15:15 Staging pathways: SNB or imaging
PRO - Y. Colson
CON - L. Spaggiari

15:30 Update on new therapies on advanced lung cancer
L. Buffoni

15:45 Discussion

16:00 Break
May 1  
Room DUBAI

16:10 - 18:30 Abstract presentations and new studies proposed

Chairmen  P. Delrio, M. Ansarin

16:10 The treatment of peripheral advanced secondary lymphedema. While the early bird catches the worm, the late riser still benefits  C. C. Campisi

16:30 - 17:30 Gastrointestinal, Urology, Head & Neck

1. The Clinical usefulness of the intraoperative detection of sentinel lymph note metastases by a rapid RT PCR system in patients with gastric cancer  M Khalid, S Yanagita, Y Uenosono, T Arigami, K Okubo, T Kijima, M Amatatsu, S Natsugoe

2. The application of ICG fluorescence sentinel node biopsy for early gastric cancer to the laparoscopic function preserving gastrectomy  S Kinami, T Oonishi, Y Fujii, J Fujita, D Kaida, Y Tomita, H Fujita, Y Nakano, N Ueda, T Kosaka

3. The sentinel lymph node procedure with isosulfan blue or fluorescence imaging shows comparable upstaging rates in patients with node negative colon cancer – A prospective comparative study  B Weixler, A Rickenbacher, DA Raptis, M Zuber


5. CLEAN NET with Sentinel Node Dissection for Early Gastric Cancer  Y Uenosono, T Arigami, K Okubo, S Natsugoe


8. Sentinel node biopsy technique in gastrointestinal tract cancer  E. Mazza, P Chiaro, M Bellò, P Cassoni, M. Morino, S. Sandrucci, M. Mistrangelo

May 1
Room DUBAI

17:30 - 18:30  Chairmen  F. Di Filippo, R. Andtbacka

1. Intradermal Stress Lymphoscintigraphy for Screening and Early Detection of Breast Cancer Related Lymphedema.
    G Tartaglione, R Bartoletti, G Visconti, M Salgarello

2. Improved lymphatic mapping for repeat sentinel node biopsy in ipsilateral breast cancer relapse using SPECT/CT
    P Borrelli, ML Donswijk, MP Stokkel, RA Valdés Olmos

3. Innovating radioguided surgery: sentinel node localization in patients with breast cancer using a freehand SPECT mobile gammas camera combination
    T Engelen, BMF Winkel, DDD Rietbergen, GH KleinJan, S Vidal Sicart, RA Valdes Olmos, NS van den Berg, FWB van Leeuwen

4. The predictive value of methylene blue dye as a single technique in breast cancer sentinel node biopsy. A study from Dharmais Cancer Hospital
    B Brahma, RI Putri, RB Andinata, L Sari, SJ Haryono

5. Feasibility of Sentinel Lymph Node Biopsy after Ipsilateral Breast Tumor Recurrence.
    Akiko Matsumoto, Hiromitsu Jinno, Maiko Takahashi, Tetsu Hayashida, Yuko Kitagawa

6. PET-CT scan vs Sentinel Node Biopsy in the detection of inguinal lymph-node metastases in patients affected by anal cancer.
    E. Mazza, A. Lesca, M. Bellò, P. Cassoni, U. Ricardi, P. Franco, P. Racca, L. Fanchini, M. Baccega, P. Chiaro, M. Morino, M. Mistrangelo

7. Sentinel node biopsy for anal carcinoma
    E. Mazza, A. Lesca, M. Bellò, P. Cassoni, U. Ricardi, P. Franco, P. Racca, L. Fanchini, P. Chiaro, M. Baccega, M. Morino, M. Mistrangelo

8. The Role Of Pet-Ct Scan In The Detection Of Inguinal Metastases In Patients Affected By Anal Cancer: A Review Of The Literature And A Comparison With Sentinel Node Biopsy And Fine Needle Aspiration
    E. Mazza, A. Lesca, M. Bellò, P. Cassoni, U. Ricard, P. Franco, P. Racca, L. Fanchini, M. Baccega, M. Morino, M. Mistrangelo

18:30  Closure
## May 2
### Room MIAMI - PANAMA

### What after positive sentinel node

#### Chairmen
- F. Di Filippo
- O.E. Nieweg

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Value of staging imaging in melanoma patients with positive sentinel lymph nodes</td>
<td>O. E. Nieweg</td>
</tr>
<tr>
<td>08:45</td>
<td>Completion lymphadenectomy after positive SLN biopsy Melanoma</td>
<td>M. Faries</td>
</tr>
<tr>
<td>09:00</td>
<td>Breast</td>
<td>F. Di Filippo</td>
</tr>
<tr>
<td>09:15</td>
<td>Oral Cavity</td>
<td>F. Ionna</td>
</tr>
<tr>
<td>09:30</td>
<td>Axillary management after neo adjuvant therapy in breast cancer</td>
<td>H. Cody III</td>
</tr>
<tr>
<td>09:45</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>

#### Chairmen
- A. Costa
- D. D’Ugo

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15</td>
<td>Adjuvant therapies of SLN + patients: Breast</td>
<td>PRO - E. Munzone, CON - M. De Laurentiis</td>
</tr>
<tr>
<td>10:45</td>
<td>Adjuvant therapies of SLN + patients: Melanoma</td>
<td>PRO - V. Chiarion Sileni, CON - S. Mocellin</td>
</tr>
<tr>
<td>11:15</td>
<td>Update on immunotherapies in adjuvant and advanced melanoma</td>
<td>P. Ascierto</td>
</tr>
<tr>
<td>11:30</td>
<td>Update on target therapy in adjuvant and advanced melanoma</td>
<td>P. Queirolo</td>
</tr>
<tr>
<td>11:45</td>
<td>Video assisted lymphadenectomy</td>
<td>A. Sommariva</td>
</tr>
<tr>
<td>12:00</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>
May 2
Room MIAMI - PANAMA
Recurrence and SNB

Chairmen  J. Gershenwald
           S. Zurrida

12:15  Follow up for morbidity and recurrence  P. G. Gill

12:30  Monitoring sentinel lymph node for circulating tumor cells (CTC) and cell-free circulating DNA/microRNA in melanoma patients  D. Hoon

12:45  SNB after melanoma metastases  M. Faries

13:00  SNB after breast recurrence  M. Intra

13:15  Discussion

13:30  Lunch
May 2
Room MIAMI - PANAMA
Sentinel node in Breast cancer

Chairmen  F. Di Filippo
           P. Veronesi

14:30  Dedicated PET devices for breast cancer
       imaging and biopsy  PM. Herranz

14:45  Sentinel Node Biopsy: still as a standard
       treatment in breast cancer surgery?  H. Cody III

15:00  The role of SNB after neo adjuvant
       therapies  V. Galimberti

15:15  Technical devices and new methods to
       detect SN  B. Ballardini

15:30  State of the art of SN histological
       evaluation: still multisection analysis?  L. Jackett

15:45  Molecular biology on primary and SNB
       to indicate adjuvant therapies  A. Spatz

16:00  Breast imaging: what's new, what is last
       A. Gallipoli
       M. Mattace-raso

16:15  Towards a new era on the role of SNB in
       breast cancer: ongoing studies report  O. Gentilini

16:30  Discussion

16:45  Break
May 2
Room MIAMI - PANAMA
Sentinel node in H&N cancer

**Chairmen**
L. Calabrese  
A. Pastore

**17:00** Update on indications and study results  
*F. Ionna*

**17:15** Molecular patterns detectable from primary disease and SNB  
*A. Anichini*

**17:30** Staging pathways: SNB or imaging  
*S. Lastoria*

**17:45** Indications for medical therapy in a multidisciplinary setting  
*L. Locati*

**18:00** Discussion

**18:15** Closure
May 2
Room DUBAI
08:00 - 09:00 Abstract presentations and new studies proposed

08:00 - 09:00  Melanoma

Chairmen  E. Pennacchioli, G. Di Monta

1. Is there a single or rare there multiple sentinel lymph nodes for melanoma?  
   DM Balkin, F. Wang, EM. Balkin, C O’Donoghue, M Kashani Sabet, JS Zager, SP Leong

2. A portable hybrid camera for fused optical and scintigraphic imaging: clinical experience in melanoma patients  
   S Vidal Sicart, A Bennássar, A Tapias, P Perlaza, N Sánchez, A Seva

3. Lymph nodes’ capsular naevi are associated with high naevus count in melanoma patients: a case control study  
   S Ribeiro, C Longo, F Specchio, G Argenziano

4. Different measurement of microscopic tumor burden and its prognostic role in sentinel lymph node in patients with cutaneous melanoma  
   G. Di Monta, U. Marone, ML. Di Cecilia, C. Caracò

5. The use of a portable gamma camera for the intraoperative detection of additional sentinel nodes in melanoma patients  
   SP Leong, M Wu, Y Lu, D Torre, MA Garrett, M Heller Benson, A Wight, C Ospina, W Luckett, M Kashani Sabet

6. When to perform a sentinel lymph node biopsy in thin melanoma?  
   E Gironés, LL Pascual, AC Iturriagagoitia, C E Estébanez

7. Report of the use of Tc 99m for SLNB in skin melanoma patients at Surgical Oncology Clinic,  
   NCRC of Serbia, Belgrade, years 2013 2014 2015  
   A Martinovic, N Santrac, M Buta, M Kocic, A Koljević Markovic, S Tasic, R Dzodic

8. Quantification of melanoma spread in the sentinel node and survival  
May 2  
Room DUBAI  
Lymphoedema Following SLN biopsy and TLND

**Chairmen**  
C. Campisi  
L. Borgognoni

09:00  
Pre and post-operative evaluation of patients at risk of lymphedema  
*M. Pinto*

09:15  
Diagnosis, staging and conservative treatment of Lymphoedema following SNB or TLND.  
*S. Leong*

09:30  
Reverse Lymphatic mapping  
*S. Klimberg*

09:45  
Lymphovascular anastomosis  
*F. Boccardo*

10:00  
Randomized study proposal to prevent lymphedema on groin-axillary  
*F. De Cian*

10:15  
Lymph node transplantation  
*J.H. Dayan*

10:30  
Discussion

10:45  
Break
May 2
Room DUBAI

Sentinel node in abdominal cancer

Chairmen | F. Corcione  
| Y. Kitagawa  

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>Technical devices and new methods</td>
</tr>
<tr>
<td>11:15</td>
<td>Update on indications and results in upper G.I.</td>
</tr>
<tr>
<td>11:30</td>
<td>Update on indications and results in colon</td>
</tr>
<tr>
<td>11:45</td>
<td>Molecular patterns detectable from primary disease, metastatic lesions and liquid biopsies</td>
</tr>
</tbody>
</table>
| 12:15 | Staging pathways on laparoscopic and robotic approach | PRO P. Bianchi  
|       |                                                                         | CON U. Fumagalli |
| 12:30 | Indications for medical therapy | A. Avallone |
| 13:00 | Discussion                                                             |
May 2
Room DUBAI

13:15 - 14:15  Melanoma

Chairmen  C. Caracò, P. Queirolo

1. Sentinel lymph node mapping using a blue dye as only method tertiary medical center experience
   D Nikolic, M Granic, M Djorjdevic, A Nikolic

2. A 17 year retrospective audit of outcome in patients undergoing sentinel lymph node biopsy in thin melanoma
   Elena Goni Girones, Jose Rey Vasalo, Juan Ignacio Yanguas Bayona, Carmen Estabanez Estebanez

3. Combined analysis of Phase III trials evaluating (99mTc) Tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node negative cutaneous melanoma
   VK Sondak, DW King, JS Zager, S Schneebaum, J Kim, SPL Leong, MB Faries, BJ Averbook, SR Martinez, CA Pulco, JL Messina, L Christman, AM Wallace

4. Gamma probe and Ultrasound Guided Fine Needle Aspiration Cytology of the Sentinel Node in Melanoma and Breast Cancer Patients
   First Results Pilot GULF Trial.
   C.M.C. Oude Ophuis, L.B. Koppert, C. de Monyé, S. Koljenović, C.H.M. van Deurzen, C. Verhoef, DJ. Grünhagen

5. Fdg pet/ct imaging as a diagnostic tool for progression evaluation of melanoma. Is it really so precise? case report
   Dejan Nikolic, Zlatko Skuric, Violeta Stanimirovic, Aleksandra Nikolic

6. Lymphoseek: a molecular imaging agent for melanoma sentinel lymph node mapping
   AM Wallace, CK Hoh, Sj Ellner, DD Darrah, G Schulteis, DR Vera

7. Routine PET/CT and Brain MRI at the time of diagnosis in patients with regional metastatic melanoma rarely identifies systemic disease.
   EP Miranda, B Jaron, M Kashani Sabet, SPL Leong

8. Prospective study on the value of repeat lymphoscintigraphy on the detection of node status in patients undergoing lymph nodal complete radical dissections for melanoma: pilot study and full protocol.
   A Testori, CR Rossi, G Mazzarol, F Verrecchia, S Gandini, F Cataldo
May 2  
Room DUBAI  
Sentinel node in gynecologic neoplasms

**Chairmen**  
S. Greggi  
M. Thill

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30</td>
<td>Update on indications and study results</td>
<td>A. van Der Zee</td>
</tr>
<tr>
<td>14:45</td>
<td>Technical devices and new methods to detect SN (Paramagnetic particles)</td>
<td>M. Thill</td>
</tr>
<tr>
<td>15:00</td>
<td>Molecular patterns detectable from primary disease and SNB</td>
<td>G. Palmieri</td>
</tr>
<tr>
<td>15:15</td>
<td>Staging pathways: SNB or imaging</td>
<td>PRO - N. Abu Rustum</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CON - V. Zanagnolo</td>
</tr>
<tr>
<td>15:45</td>
<td>Indications for medical therapy in a multidisciplinary setting</td>
<td>N. Colombo</td>
</tr>
<tr>
<td>16:00</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>16:15</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>
May 2  
**Room DUBAI**

Sentinel node in prostate cancer

**Chairmen**  
S. Perdonà  
G. Renne  
F. Wawroschek

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30</td>
<td>Update on indications and study results</td>
<td>F. Wawroschek</td>
</tr>
<tr>
<td>16:45</td>
<td>Technical devices and new methods to detect SN</td>
<td>H. G. van Der Poel</td>
</tr>
<tr>
<td>17:00</td>
<td>Atypical lymph node metastatic sites and SLNB</td>
<td>R. Montironi</td>
</tr>
<tr>
<td>17:15</td>
<td>Robotic surgery on prostate cancer+/-SNB</td>
<td>O. De Cobelli</td>
</tr>
<tr>
<td>17:30</td>
<td>Update on immunotherapies on advanced urological cancer</td>
<td>A. Pignata</td>
</tr>
<tr>
<td>17:45</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td>Closure</td>
<td></td>
</tr>
<tr>
<td>Sponsor</td>
<td>Sponsor</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>agenus</td>
<td>MSD Be well</td>
<td></td>
</tr>
<tr>
<td>HEMO-DIAGNOSTICA</td>
<td>ONCOVISION</td>
<td></td>
</tr>
<tr>
<td>MERCK</td>
<td>iTheraMedical</td>
<td></td>
</tr>
<tr>
<td>sysmex</td>
<td>Navidea BIOPHARMACEUTICALS</td>
<td></td>
</tr>
<tr>
<td>ICEA CLINICAL BIOPHYSICS</td>
<td>MAVIG VivaScope</td>
<td></td>
</tr>
<tr>
<td>NOVODIAX</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Con il patrocinio del Ministero della Salute
The sentinel Node in the era of individualized management of cancer patients

Faculty

Abu Rustum Nadeem, Memorial Sloan Kettering Cancer Center - New York - USA
Andtbacka Robert, University Of Utah - Salt Lake City - USA
Anichini Andrea, Istituto Nazionale Tumori - Milano - Italia
Ansarin Mohssen, Istituto Europeo di Oncologia - Milano - Italia
Ascierto Paolo, Istituto Nazionale Tumori - Napoli - Italia
Avalone Antonio, Istituto Nazionale Tumori - Napoli - Italia
Balch Charles, University of Texas - Southwestern Medical Center - Dallas - USA
Bardelli Alberto, Istituto Per La Ricerca E Cura Del Cancro Di Candiolo - Torino - Italia
Ballardini Bettina, Istituto Europeo di Oncologia - Milano - Italia
Bianchi Paolo Pietro, Ospedale Civile di Grosseto - Italia
Biffi Roberto, Istituto Europeo di Oncologia - Milano - Italia
Boccardo Francesco, Istituto Nazionale per la ricerca sul cancro - Genova - Italia
Borgognoni Lorenzo, Azienda Ospedaliera Toscana Centro, Italia
Botti Gerardo, Istituto Nazionale Tumori - Napoli - Italia
Buffoni Lucio, Ospedale Molinette - Torino - Italia
Calabrese Luca, Istituto Europeo di Oncologia - Milano - Italia
Campisi Corradino, Istituto Nazionale per la ricerca sul cancro - Genova - Italia
Campisi Corrado, Università Degli Studi Di Genova - Italia
Caraco’ Corrado, Istituto Nazionale Tumori - Napoli - Italia
Catalano Orlando, Istituto Nazionale Tumori - Napoli - Italia
Chiarion Sileni Vanna, Istituto Oncologico Veneto - Padova - Italia
Ciliberto Gennaro, Istituto Nazionale Tumori - Napoli - Italia
Cochran Alistair, Ronald Regan Ucla Medical Center - Los Angeles - USA
Cody Hiram, Memorial Sloan Kettering Cancer Center - New York - USA
Coit Daniel, Memorial Sloan Kettering Cancer Center - New York - USA
Colleoni Marco, Istituto Europeo di Oncologia - Milano - Italia
Colombo Nicoletta, Istituto Europeo di Oncologia - Milano - Italia
Colson Yolonda, Brigham & Women’s Hospital - Boston - USA
Corcione Francesco, Ospedale Monaldi - Napoli - Italia
Costa Alberto, European School of Oncology - Milano - Italia
Dayan Joseph, Memorial Sloan Kettering Cancer Center - New York - USA
De Cian Franco, Università degli Studi di Genova - Italia
De Cobelli Ottavio, Istituto Europeo di Oncologia - Milano - Italia
De Laurentiis Michielino, Istituto Nazionale Tumori - Napoli - Italia
Delrio Paolo, Istituto Nazionale Tumori - Napoli- Italia
Di Filippo Franco, Istituto Fisioterapico Italiano Regina Elena - Roma - Italia
Di Monta Gianluca, Istituto Nazionale Tumori - Napoli - Italia
D’Ugo Domenico, Ospedale Policlinico Universitario Agostino Gemelli - Roma - Italia
Faries Mark, John Wayne Cancer Institute - Santa Monica - USA
Fumagalli Uberto, Humanitas Research Hospital - Milano - Italia
Galimberti Viviana Enrica, Istituto Europeo di Oncologia - Milano - Italia

The sentinel Node in the era of individualized management of cancer patients
The sentinel Node in the era of individualized management of cancer patients

Ross Merrick, Anderson Cancer Center - Houston - USA
Rossi Carlo Riccardo, Istituto Oncologico Veneto - Padova - Italia
Saha Sukamal, McLaren Regional Medical Center - Flint - USA
Santambrogio Luigi, Ospedale Maggiore Policlinico Mangiagalli e Regina Elena - Milano - Italia
Sapino Anna, Fondazione Piemontese per la ricerca sul cancro - Istituto Di Candiolo - Pordenone - Italia
Schittulli Francesco, Presidente Lega Italiana Lotta ai Tumori - Bari - Italia
Sommariva Antonio, Istituto Oncologico Veneto - Padova - Italia
Soteldo Javier, Hospital De Clinicas - Caracas - Venezuela
Spaggiari Lorenzo, Istituto Europeo di Oncologia - Milano - Italia
Spyt Alan, Jewish General Hospital - Montreal - Canada
Starz Hans, Labor Fur Dermatohistologie und Oralpathologie - Munchen - Germany
Takeuchi Hiroya, Keio University - Tokyo - Japan
Tejera-Vaquerizo Antonio, Clinica Dermatologica Globalderm - Cordoba - Spain
Testori Alessandro, Istituto Europeo di Oncologia - Milano - Italia
Thill Marc, Cancer Center at Agaplesion Markus Hospital - Frankfurt - Germany
Thompson John, Royal Prince Alfred Hospital - Camperdown - Australia
Uren Roger, Rpa Medical Center - Newtown - Australia
Valdes-Olmos Renato, Netherlands Cancer Institute - Amsterdam - Netherlands
Van Akkooi Alexander, Netherlands Cancer Institute - Amsterdam - Netherlands
Van Der Poel H.G., Netherlands Cancer Institute - Amsterdam - Netherlands
Van Der Zee Ate, University Medical Center Groningen - Groningen - Netherlands
Van Leeuwen Fijs, Leiden University Medical Center - Leiden - Netherlands
Veronesi Paolo, Istituto Europeo di Oncologia - Milano - Italia
Veronesi Umberto, Istituto Europeo di Oncologia - Milano - Italia
Viale Giuseppe, Istituto Europeo di Oncologia - Milano - Italia
Vidal-Sicart Sergi, Hospital Clinic de Barcellona - Barcellona - Spain
Wallace Anne, Moores Cancer Center - San Diego - USA
Wawroschek Friedheim, Klinikum Oldenburg - Oldenburg - Germany
Yamamoto Maki, University of California Irvine - Orange - USA
Zanagnolo Vanna, Istituto Europeo di Oncologia - Milano - Italia
Zurrida Stefano, Università degli Studi - Milano - Italia
Participants who wish to submit a poster or oral communication within the Congress, must be sent an abstract within March the 4th 2016:

**Note: the characteristics of the abstract:**
- max 1 page A4
- times New Roman 12 pt

**The structure of the Abstract must be as follows:**
- introduction
- M & M
- results
- conclusion


**ACCOMODATION**
The ISNS 2016 Biannual Meeting organization has entered into the following agreements with these hotels:

<table>
<thead>
<tr>
<th>HOTEL</th>
<th>PRICE</th>
</tr>
</thead>
<tbody>
<tr>
<td>NHOW Hotel ****</td>
<td>€ 129.00</td>
</tr>
<tr>
<td>Hotel Minerva ***</td>
<td>€ 80.00</td>
</tr>
<tr>
<td>Hotel Des Etrangers ***</td>
<td>€ 68.00 plus breakfast per night</td>
</tr>
<tr>
<td>Hotel Sant’Ambroeus ***</td>
<td>€ 60.00 plus breakfast per night</td>
</tr>
<tr>
<td>Isola Libera (B&amp;B)</td>
<td>€ 65.00</td>
</tr>
<tr>
<td>Hotel Carrobbio ****</td>
<td>€ 70,00 single room</td>
</tr>
<tr>
<td></td>
<td>€ 100,00 double room</td>
</tr>
</tbody>
</table>